Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-26T17:31:38.443Z Has data issue: false hasContentIssue false

EPA-0324 – Role of Glucocorticoid Receptors in Mood Disorders

Published online by Cambridge University Press:  15 April 2020

C. Pariante*
Affiliation:
Psychological Medicine, Institute of Psychiatry King's College London, London, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

This tall will review the work conducted within Moodinflame around the role of the glucocorticoid receptor in both cellular models of neurogenesis and in clinical samples of depressed patients. In our established model of ‘depression in a dish’, using human neuronal stem cells, we have found that the glucocorticoid receptor is the target of both glucocorticoid (stress) hormones and of antidepressants, with the ability of both inhibit and stimulate neurogenesis in the hippocampus. In addition, reduced glucocorticoid receptor function and expression in the peripheral blood depressed patients is a consistent finding across clinical samples as diverse as young adults, older depressed patients with coronary heart diseases, and patients with cytokine-induced depression. This body of research confirms the pivotal role of the glucocorticoid receptor, and the potential clinical relevance of targeting it for therapeutic antidepressant purposes.

Type
S512 - Symposium: Results from EU Consortium Moodinflame: integrative view on mood disorders
Copyright
Copyright © European Psychiatric Association 2014

References

Anacker, C., Cattaneo, A., Musaelyan, K., Zunszain, P.A., Horowitz, M., Molteni, R., Luoni, A., Calabrese, F., Tansey, K., Gennarelli, M., Thuret, S., Price, J., Uher, R., Riva, M.A., Pariante, C.M.Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proc Natl Acad Sci U S A 2013May 21; 110(21):87088713CrossRefGoogle ScholarPubMed
Anacker, C., Cattaneo, A., Luoni, A., Musaelyan, K., Zunszain, P.A., Milanesi, E., Rybka, J., Berry, A., Cirulli, F., Thuret, S., Price, J., Riva, M.A., Gennarelli, M., Pariante, C.M.Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis. Neuropsychopharmacology 2013Apr; 38(5):872883CrossRefGoogle ScholarPubMed
Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K.J., Craig, I.W., Anacker, C., Zunsztain, P.A., McGuffin, P., Pariante, C.M.Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology 2013Frb; 38(3):377385CrossRefGoogle Scholar
Zunszain, P.A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A.M., Thuret, S., Price, J., Pariante, C.M.Interleukin-1β: A new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology. 2012Mar; 37(4):939949CrossRefGoogle ScholarPubMed
Anacker, C., Zunszain, P.A., Cattaneo, A., Carvalho, L.A., Garabedian, M.J., Thuret, S., Price, J., Pariante, C.M.Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry. 2011Jul; 16(7):738750CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.